Silicon Therapeutics is designing novel small molecule therapeutics atom-by-atom to address the most challenging protein targets in medicine. We’re focused on biologically and genetically validated protein targets that have, until now, been considered “undruggable.”
Our drug design process is built on three essential concepts: our multi-disciplinary team; integrated approach and deep physics insights; and our leadership in understanding conformational modulation.
The Silicon Therapeutics multidisciplinary team of experts includes software engineers, parallel computing experts, quantum physicists, chemists, biologists and clinicians. We fuse the expertise and insights of our teams to eliminate barriers and improve communication.Multidisciplinary Team
The Silicon Therapeutics fully integrated approach to drug discovery and development enables us to design small molecule therapeutic candidates for challenging targets in areas of unmet medical need.Integrated Approach
Conformational genetics is the engine we use at Silicon Therapeutics for selecting targets and defining our design strategy. The relationship between human disease genetics and the associated conformational mechanism that influences pathway signaling informs about us how to design drugs that appropriately modulate the target for therapeutic effect.Conformational Genetics